(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of 0.86% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 264.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.14%.
Emergent Biosolutions's revenue in 2025 is $788,900,000.On average, 4 Wall Street analysts forecast EBS's revenue for 2025 to be $41,751,795,781, with the lowest EBS revenue forecast at $40,305,921,172, and the highest EBS revenue forecast at $43,626,233,296. On average, 3 Wall Street analysts forecast EBS's revenue for 2026 to be $49,783,148,676, with the lowest EBS revenue forecast at $35,102,243,139, and the highest EBS revenue forecast at $65,912,554,820.
In 2027, EBS is forecast to generate $33,948,904,730 in revenue, with the lowest revenue forecast at $32,940,521,421 and the highest revenue forecast at $35,293,415,808.